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The SARS coronavirus main proteinase is a prime tar-
get for antiviral therapy. In this issue of Chemistry &
Biology, Wu et al. describe potent inhibition of the
enzyme by benzotriazole esters, which were originally
obtained as intermediates in the synthesis of lopinavir
derivatives [1].
Since the discovery of HIV-1 proteinase in the mid-
1980s, this enzyme probably has become the best-
characterized peptidase, with several hundreds of crys-
tal structures of inhibitor complexes determined to date.
However, the main proteinase of SARS coronavirus
(Mpro, also called 3CLpro) has a good chance to catch
up. When the first three-dimensional structure of a coro-
navirus Mpro was published in 2002, that of the enzyme
from transmissible gastroenteritis virus (TGEV) [2], inter-
est in the coronaviridae was only moderate, since these
viruses were considered relatively harmless to human
health. This assessment changed dramatically in late
March, 2003, when it was found that the ongoing global
outbreak of the highly infectious severe acute respira-
tory syndrome was caused by a new coronavirus, sub-
sequently named SARS-CoV. Since then, efforts to dis-
cover anti-SARS drugs have been numerous, in order to
be prepared should the virus raise its ugly head again.
Coronavirus genomes code for two large polyproteins,
pp1a and pp1ab, that are processed by viral proteinases
to yield the individual components of the large replicase
complex. Most coronaviruses have three cysteine pro-
teinases that are responsible for this processing: two
papain-like proteinases and the main proteinase, Mpro.
Interestingly, one of the two papain-like proteinases is
absent in the SARS coronavirus, and the other one has
been shown to have the additional function of a deubiqui-
tinating enzyme [3, 4]. While the papain-like proteinases
together are only responsible for three cleavage reac-
tions near the N terminus of the polyproteins, the Mpro
cleaves these huge substrates (molecular masses of
450–750 kDa) at no less than 11 sites. Since this reaction
is essential for viral replication, the main proteinase is
obviously a prime target for interference by inhibitors [5].
As a first step toward inhibitor design for coronavirus
Mpros, the crystal structure was elucidated for a complex
between the TGEV enzyme and a hexapeptidyl chloro-
methyl ketone inhibitor that had an amino acid sequence
corresponding to the specificity of the enzyme [6]. The
mode of binding of this inhibitor to the target enzyme
was found to be related (although not identical) to what
had been seen earlier in a complex between the rhinovi-
rus (HRV-2) 3C proteinase and compound AG7088 (Fig-
ure 1A), a vinylogous ethyl ester developed by Agouron
Inc. (now a division of Pfizer) for the treatment of the
common cold caused by rhinoviruses [7]. This observa-
tion led to the proposal that AG7088 should be a good
starting point for the design of anti-SARS inhibitors [6].The crystal structures of the main proteinases of hu-
man coronavirus 229E and then of the SARS virus itself
were solved within weeks after identification of the new
virus [6, 8]. The structural insight along with information
on the flexibility of the enzyme [9] enabled researchers
world-wide to use structure-based design [5] and virtual
screening methods [10] to prepare new inhibitors of the
SARS-CoV Mpro. Several derivatives of AG7088 (Fig-
ure 1B-D) have been described, which are much more
active than the parent compound while displaying low
toxicity in cell assays [11].
Originally, SARS patients in Hong Kong and Toronto
were treated with ribavirin. When it surfaced that this
compound is not efficient against the virus, at least not
at nontoxic concentrations, HIV proteinase inhibitors
were tested preclinically. Surprisingly, some but not all
of these did inhibit the SARS-CoV main proteinase
in vitro and in cell culture. Thus, Wong and co-workers
found that lopinavir (Figure 1E) inhibited the Mpro with
an IC50 ofw50 mM [12].
The new contribution from the same group, presented
in this issue [1], originated from an attempt to improve
the inhibitory properties of lopinavir. The authors assem-
bled a library of lopinavir-like compounds by coupling an
amine or a 1,4-diamine with various acids in microtiter
plates, followed by screening in situ. O-(Benzotriazol-1-
yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate
(HBTU) was used as a coupling reagent. Several lopinavir
derivatives showed somewhat improved binding affini-
ties, but it came as a big surprise that some of the inter-
mediate benzotriazole esters resulting from the activa-
tion of the acid components by HBTU were nanomolar
inhibitors of the Mpro! Thus, we have the remarkable
case here of a reaction intermediate being a highly active
inhibitor of a target enzyme. Next, the authors synthe-
sized a series of benzotriazole esters (Figure 1F) by con-
densation of HBTU with various aromatic carboxylic
acids and found that compounds carrying electron-do-
nating substituents were strong irreversible inhibitors
of the Mpro, with a Ki of 21.0 nM for the best derivative.
Using mass spectrometry, Wu et al. showed that the
compounds acted by acylating the catalytic cysteine
residue of the Mpro. Further, they also demonstrated
that the benzotriazole derivatives were non-toxic to
Vero E6 cells, the standard cells used in anti-SARS-
CoV assays, at a concentration of 100 mM [1].
Yet, it is clear that these inhibitors are quite far from
being drugs useable for treating coronavirus infections
and SARS. Because of their mode of action, it seems
likely that they will inhibit cellular cysteine proteinases
as well as the viral one. However, these acylating com-
pounds could potentially be modified by substituents
occupying the S1 and S2 specificity pockets of the en-
zyme and are therefore useful starting points for design-
ing more specific inhibitors.
As reactivity and specificity often counteract each
other, it would be desirable to have inhibitors of the
SARS-CoV main proteinase that do not covalently mod-
ify the catalytic cysteine residue. In their paper, Wu et al.
[1]alsodescribebenzotriazoleestersurrogates thathave
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thus not susceptible to nucleophilic attack by the active
site cysteine. Some of these compounds (such as 14, 17,
and 18; see Scheme 3 of Wu et al. [1]) are competitive in-
hibitors with Ki values in the lower micromolar range and
are thus among the most potent noncovalent inhibitors
Figure 1. Chemical formulas of (A) AG7088, (B-D) AG7088 deriva-
tives, (E) lopinavir, (F) 1-(benzoyloxy)-benzotriazole (R=4-NHCH3,
4-N(CH3)2, or 4-N(C2H5)2).Chemistry & Biology 13, March 2006 ª2006 Elsevier Ltd All rights reserved D
Pharmacogenetics:
Yeast Lead the Way
In this issue of Chemistry & Biology, Perlstein et al. [1]
use genetically diverse strains of yeast to study the
genetic basis of differences in cellular responses toof the SARS-CoV Mpro described to date. The discovery
of compounds binding noncovalently to the Mpro may, in
the end, constitute a more important milestone on the
way to clinically useful inhibitors of the coronavirus main
proteinase than identification of the acylating agents.
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small molecules. Their results suggest that drug re-
sponses are regulated by a limited number of loci,
and that this system can identify clusters of function-
ally similar molecules.
When given a standard dose of commonly prescribed
drugs, a significant fraction of patients will either receive
